MolMed is a clinical biotech company focused on research, development, manufacturing and clinical validation of innovative therapies in oncology and immuno-oncology
Patient-specific cell therapy based on the use of the TK suicide gene, allowing the transplantation of hematopoietic stem cells from partially matched donors, in the absence of immunosuppression
CAR-T CD44v6: Immune gene-therapy autologus product, consisting of T lymphocytes genetically modified to express the CAR, which allows selective recognition and elimination of tumor cells expressing the CD44v6 antigen
Other CAR-T: CAR-T cells that target other tumor antigens. The targets have been chosen with a multidisciplinary approach in order to be potentially effective against both hematological malignancies and solid tumors
Innovative CAR platform based on Natural Killer cells to develop "off-the-shelf" products, able to treat many patients with a single manufactured batch
Recombinant protein that allows to increase the concentration of immunity cells and chemotherapeutic drugs at the tumor level through the permeabilization of tumor vessels
Our proprietary pipeline includes products in clinical and preclinical stage: Zalmoxis® (TK), a cell therapy used in haploidentical transplants authorized for the EU market, the CAR-T CD44v6, targeting both liquid and solid tumors and a new CAR pipeline of autologus and allogeneic products.